# Personalized Translational Platform for Biomarker Discovery in Brain Tumors

> **NCT01240161** · — · COMPLETED · sponsor: **Marcelo F. Di Carli, MD, FACC** · enrollment: 37 (actual)

## Conditions studied

- High Grade Glioma

## Interventions

- **DRUG:** FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT

## Key facts

- **NCT ID:** NCT01240161
- **Lead sponsor:** Marcelo F. Di Carli, MD, FACC
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2017-08-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01240161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01240161, "Personalized Translational Platform for Biomarker Discovery in Brain Tumors". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT01240161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*